Athersys, Inc. Receives Orphan Drug D...

Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

There are 2 comments on the BioSpace story from Jul 10, 2012, titled Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome. In it, BioSpace reports that:

Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more)

Join the discussion below, or Read more at BioSpace.

athxer

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.
athxer

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
News Obama asks Congress for $1.8 billion to fight Zika 21 hr Guru 11
News Premature Ejaculation Drug (Jul '06) Jan 31 Dr Wu 33
News Drugmaker Pfizer sees profit gain after acquisi... (May '10) Jan 31 Noell 18
News Vivus Wins FDA Approval (Aug '12) Jan 31 Tara 13
News Earnings Preview: Pfizer to report 2Q earnings (Aug '10) Jan 31 Sharolyn 18
News Q1 2016 EPS Estimates for McKesson Co. (MCK) De... Jan 30 Syntax Error 1
News Bristol-Myers Squibb Co (BMY) Stake Raised by B... Jan 30 Syntax Error 1
More from around the web